Clinical Research

Clinical ResearchRevascularization is performed on pernament teeth that have become necrotic and infected and are immature.

In one study (Takushige T, eta!. Endodontic Treatment  of Primary Teeth Using a Combination of Antibacterial Drugs. International) applied this theory clinically in a trial involving 87 infected primary  molars.   The results showed that 83 of the 87 cases demonstrated healing after one application  of treatment.  In those 83 cases, pain, swelling, and fistulas resolved within  one week of the therapy.  (Mean observation  period - 680 days)


Nonsurgical Healing of Large Periradicular Lesions using a Triple Antibiotic Paste: A case series

Contemp Clin Dent. 2010 Jan-Mar; 1(1): 31–35. 

Sonali Taneja, Manju Kumari, and Hari Parkash1

The infection of the root canal system is considered to be a polymicrobial infection, consisting of both aerobic and anaerobic bacteria. Because of the complexity of the root canal infection, it is unlikely that any single antibiotic could result in effective sterilization of the canal. A combination of antibiotic drugs (metronidazole, ciprofloxacin, and minocycline) is used to eliminate target bacteria, which are possible sources of endodontic lesions. Three case reports describe the nonsurgical endodontic treatment of teeth with large periradicular lesions. A triple antibiotic paste was used for 3 months. After 3 months, teeth were asymptomatic and were obturated. The follow-up radiograph of all the three cases showed progressive healing of periradicular lesions. The results of these cases show that when most commonly used medicaments fail in eliminating the symptoms then a triple antibiotic paste can be used clinically in the treatment of teeth with large periradicular lesions.

Disinfection of Immature Teeth with a Triple Antibiotic Paste.

J Endod. 2005 Jun;31(6):439-43.

Windley W 3rd, Teixeira F, Levin L, Sigurdsson A, Trope M.

This study assessed the efficacy of a triple antibiotic paste in the disinfection of immature dog teeth with apical periodontitis. The canals were sampled before (S1) and after (S2) irrigation with 1.25% NaOCL and after dressing with a triple antibiotic paste (S3), consisting of metronidazole, ciprofloxacin, and minocycline. At S1, 100% of the samples cultured positive for bacteria with a mean CFU count of 1.7 x 10. At S2, 10% of the samples cultured bacteria-free with a mean CFU count of 1.4 x 10. At S3, 70% of the samples cultured bacteria-free with a mean CFU count of only 26. Reductions in mean CFU counts between S1 and S2 (p < 0.0001) as well as between S2 and S3 (p < 0.0001) were statistically significant. These results indicate the effectiveness of a triple antibiotic paste in the disinfection of immature teeth with apical periodontitis.


Treatment of immature teeth with non-vital pulps and apical periodontitis by Martin Trope


Before using PulpVaz, please assess the patient for allergies to Ciprofloxacin, Metronidazole, Clindamycin, (iodine – on the PV3i form), and propylene glycol.  *This has been added to the formula to allow the product to be radio opaque upon x-ray.


MedCara Pharmaceuticals
126 N Main
Conrad, Iowa 50621
Phone: 515.577.6758 |Email
NuCara Pharmacy
1150 5th Street, Suite 140
Coralville, Iowa 52241
Toll Free Ph: 877.268.2272
Ph: 319.354.6006|Fx: 866.354.6381|Email
MedCara Pharmaceuticals NuCara Pharmaceuticals
© 2021 MedCara Pharmaceuticals. All rights reserved. Sitemap|Feedback
The information contained in this website is provided for educational purposes only and is not intended to replace discussions with your healthcare provider. All decisions regarding a patients' treatment must be made with a healthcare provider. PulpVAZ� and PulpHEALTM are available as a compounded medication exclusively from MedCara Pharmaceuticals and dispensed under an exclusive contract by NuCara Pharmacy. PulpVAZ and PulpHEAL as formulations have not been through FDA testing. PulpVAZ and PulpHEAL have been compounded under prescription from a licensed professional and is dispensed under a specific patient name. MedCara Pharmaceuticals and NuCara Pharmacy does not make any claims, overt or implied, of the safety or effectiveness of the PulpVAZ or PulpHEAL compounds. We refer only to references pertaining to peer reviewed medical publications and/or safety studies endorsed by the FDA. In keeping with FDA regulations, MedCara Pharmaceutical�s intentions are to provide pertinent and informative facts and information that will assist a person in making a well informed and educated decision about his/her medical care.
© 2021 MedCara Pharmaceuticals. All Rights Reserved.